SLCO1B1 c.521T>C gene polymorphism decreases hypoglycemia risk in sulfonylurea-treated type 2 diabetic patients

Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis

(2021) Jeong Yee et al.   CLINICAL THERAPEUTICS

Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas

(2021) Adem Y. Dawed et al.   DIABETES CARE

Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers

(2021)   Clinical Diabetes

Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update

(2020) Lorraine Lipscombe et al.   Canadian Journal of Diabetes

Interaction of Sulfonylureas with Liver Uptake Transporters OATP1B1 and OATP1B3

(2018) Yu Chen et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population

(2018) Qi Pei et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide

(2018) Fayou Yang et al.   Scientific Reports

Characterization of OATP1B3 and OATP2B1 transporter expression in the islet of the adult human pancreas

(2017) Michelle Kim et al.   HISTOCHEMISTRY AND CELL BIOLOGY

Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?

(2017) Choon Ok Kim et al.   Drug Design Development and Therapy

CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes

(2016) Adem Y. Dawed et al.   DIABETES CARE

Management of type 2 diabetes in adults: summary of updated NICE guidance

(2016) Hugh McGuire et al.   BMJ-British Medical Journal

Management of type 2 diabetes in adults: summary of updated NICE guidance

(2016) Hugh McGuire et al.   BMJ-British Medical Journal

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

(2014) L B Ramsey et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients

(2014) Jasna Klen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

CYP2C9*2 Allele Increases Risk for Hypoglycemia in POR*1/*1 Type 2 Diabetic Patients Treated with Sulfonylureas

(2014) G. Ragia et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population

(2014) E. Giannakopoulou et al.   MOLECULAR BIOLOGY REPORTS

International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms

(2013) K M Giacomini et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

OATP1B3 Is Expressed in Pancreatic  -Islet Cells and Enhances the Insulinotropic Effect of the Sulfonylurea Derivative Glibenclamide

(2013) H. E. Meyer zu Schwabedissen et al.   DIABETES

Organic Anion Transporting Polypeptides Expressed in Pancreatic Cancer May Serve As Potential Diagnostic Markers and Therapeutic Targets for Early Stage Adenocarcinomas

(2013) Amanda Hays et al.   PHARMACEUTICAL RESEARCH

The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

(2012) R A Wilke et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated Type 2 diabetic patients

(2012) Georgia Ragia et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers

(2012) Yu Cheng et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting

(2011) Osman Gökalp et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity

(2011) Ute I. Schwarz et al.   Pharmacogenetics and Genomics

Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective

(2011) Vangelis G Manolopoulos et al.   PHARMACOGENOMICS

Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

(2011) M. Niemi et al.   PHARMACOLOGICAL REVIEWS

Expression of organic anion-transporting polypeptides 1B3, 1B1, and 1A2 in human pancreatic cancer reveals a new class of potential therapeutic targets

(2011) Evangelos Briasoulis et al.   OncoTargets and Therapy

Diabetes and Cancer: A consensus report

(2010) E. Giovannucci et al.   DIABETES CARE

The Role of Organic Anion–Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics

(2009) N Picard et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Presence ofCYP2C9*3allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas

(2009) Georgia Ragia et al.   PHARMACOGENOMICS

Influence of Drug Transporters and UGT Polymorphisms on Pharmacokinetics of Phenolic glucuronide Metabolite of Mycophenolic Acid in Japanese Renal Transplant Recipients

(2008) Masatomo Miura et al.   THERAPEUTIC DRUG MONITORING

No significant effect ofSLCO1B1polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone

(2007) Annikka Kalliokoski et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY